# US 2022/0276249 A1 · Protein signature for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0276249 A1
- Document ID: US20220276249A1
- Status: Published application
- Kind: A1
- Application number: 17/434,976
- Filed: 2020-02-28
- Published: 2022-09-01
- Earliest claimed: 2019-03-01
- Assignees: Advanced Marker Discovery, S.L.
- Applicants: Advanced Marker Discovery S.L.
- Inventors: Ana Carmen Martín Rodríguez; Rosa Pérez Palacios; Rocío Arroyo Arranz
- Web page: https://patentgrep.com/patent/US20220276249A1

## CPC

- G01N 33/57535: of the large intestine, e.g. colon, rectum or anus
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- G01N 2333/52: Assays involving cytokines
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention refers to an in vitro method for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof.

## Claims

### Claim at position 1

1-8. (canceled)

### Claim 9

A method for detecting a protein biomarker in a biological sample from a subject at risk of developing colorectal cancer or a pre-cancerous stage of colorectal cancer, said method comprising:
(a) contacting the biological sample with a reagent capable of specifically binding Flt3L and a reagent capable of specifically binding CYFRA21-1; and
(b) measuring level of Flt3L and CYFRA21-1 in the biological sample.

### Claim 10 (depends on 9)

The method of claim 9, further comprising measuring level of AREG.

### Claim 11 (depends on 10)

The method of claim 10, further comprising measuring level of ErbB4 or CLEC2C.

### Claim 12 (depends on 9)

The method of claim 9, wherein the reagent capable of specifically binding Flt3L and the reagent capable of specifically binding CYFRA21-1 are each an enzyme-linked immunosorbent assay (ELISA) reagent or a chemiluminescence immunoassay (CLIA) reagent.

### Claim 13 (depends on 9)

The method of claim 9, wherein the pre-cancerous stage of colorectal cancer is advanced colorectal adenoma.

### Claim 14 (depends on 9)

The method of claim 9, wherein said biological sample is a minimally invasive biological sample.

### Claim 15 (depends on 14)

The method of claim 14, wherein said minimally invasive biological sample is a blood sample, a serum sample or a plasma sample.

### Claim 16 (depends on 9)

The method of claim 9, further comprising performing colonoscopy on the subject.

### Claim 17

A method for treating a subject having colorectal cancer or a pre-cancerous stage of colorectal cancer, the method comprising administering to the subject a therapy for colorectal cancer or pre-cancerous stage of colorectal cancer, wherein a biological sample from the subject has been determined to have a deviation or a variation in the level of Flt3L and CYFRA21-1 as compared to a control sample.

### Claim 18 (depends on 17)

The method of claim 17, wherein the biological sample from the subject has been determined to have a decreased level of Flt3L as compared to a control sample and an increased level of CYFRA21-1 as compared to a control sample.

### Claim 19 (depends on 17)

The method of claim 17, wherein the biological sample has been further determined to have a deviation or a variation in the level of AREG as compared to a control sample.

### Claim 20 (depends on 19)

The method of claim 19, wherein the biological sample has been further determined to have an increased level of AREG as compared to a control sample.

### Claim 21 (depends on 17)

The method of claim 17, wherein the biological sample has been further determined to have a deviation or a variation in the level of ErbB4 or CLEC2C as compared to a control sample.

### Claim 22 (depends on 21)

The method of claim 21, wherein the biological sample has been further determined to have a decreased level of ErbB4 or an increased level of CLEC2C as compared to a control sample.

### Claim 23 (depends on 17)

The method of claim 17, comprising, prior to therapy, performing colonoscopy on the subject.

### Claim 24 (depends on 17)

The method of claim 17, wherein said therapy comprises removing colorectal cancer or a polyp.

### Claim 25 (depends on 17)

The method of claim 17, wherein said biological sample is a minimally invasive biological sample.

### Claim 26 (depends on 25)

The method of claim 25, wherein said biological sample is a blood sample, a serum sample or a plasma sample.

### Claim 27

A kit comprising reagents for determining the level of protein biomarkers Flt3L and CYFRA21-1 and instructions for use.
